Sustained efficacy over 1 year of treatment with erenumab: results from the extension phase of the STRIVE study in episodic migraine

被引：0
|
作者：
Goadsby, Peter J. [1 ]
Reuter, Uwe [2 ]
Hallstrom, Yngve [3 ]
Broessner, Gregor [4 ]
Bonner, Jo H. [5 ]
Zhang, Feng [6 ]
Sapra, Sandhya [6 ]
Chou, Denise E. [6 ]
Klatt, Jan [7 ]
Picard, Hernan [6 ]
Lenz, Robert A. [6 ]
Mikol, Daniel D. [6 ]
机构：
[1] Kings Coll Hosp London, NIHR Wellcome Trust Kings Clin Res Facil, London, England
[2] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
[3] St Gorans Univ Hosp, Neuro Ctr, Stockholm, Sweden
[4] Med Univ Innsbruck, Headache Outpatient Clin, Dept Neurol, Innsbruck, Austria
[5] Mercy Res, St Louis, MO USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
[7] Novartis Pharma AG, Basel, Switzerland
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P20
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study
    Ferrari, Michel Dominique
    Reuter, Uwe
    Goadsby, Peter J.
    Lima, Gabriel Paiva da Silva
    Mondal, Subhayan
    Wen, Shihua
    Tenenbaum, Nadia
    Pandhi, Shaloo
    Lanteri-Minet, Michel
    Stites, Tracy
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021,
  • [22] EFFECT OF ERENUMAB ON PATIENT-REPORTED OUTCOMES IN EPISODIC MIGRAINE PATIENTS WITH PRIOR PROPHYLACTIC TREATMENT FAILURE: RESULTS FROM A POST HOC ANALYSIS OF THE STRIVE STUDY
    Pascual, J.
    Buse, D. C.
    Starling, A.
    Ailani, J.
    Zhang, F.
    Wen, S.
    Bilitou, A.
    Desai, P.
    Picard, H.
    Klatt, J.
    Mikol, D. D.
    CEPHALALGIA, 2018, 38 : 47 - 48
  • [23] Three-Year Efficacy and Safety of Erenumab in Participants with Episodic Migraine and 2-4 Prior Preventive Treatment Failures: Results from the LIBERTY Study
    Reuter, Uwe
    Goadsby, Peter
    Ferrari, Michel
    Lima, Gabriel Paiva da Silva
    Mondal, Subhayan
    Wen, Shihua
    Stites, Tracy
    Arkuszewski, Michal
    Lanteri-Minet, Michel
    Pandhi, Shaloo
    NEUROLOGY, 2022, 98 (18)
  • [24] Three-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: Results from the LIBERTY study
    Reuter, U.
    Goadsby, P. J.
    Ferrari, M.
    Lima, G. Paiva Da Silva
    Mondal, S.
    Wen, S.
    Stites, T.
    Arkuszewski, M.
    Lanter-Minet, M.
    Pandhi, S.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [25] Three-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: Results from the LIBERTY study
    Reuter, U.
    Goadsby, P. J.
    Ferrari, M.
    Lima, G. Paiva da Silva
    Mondal, S.
    Wen, S.
    Stites, T.
    Arkuszewski, M.
    Lanter-Minet, M.
    Pandhi, S.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 268 - 268
  • [26] SUSTAINED EFFICACY AND SAFETY OF ERENUMAB IN EPISODIC MIGRAINE PATIENTS FAILING 2-4 PRIOR PREVENTIVE TREATMENTS: 2-YEAR INTERIM RESULTS OF THE LIBERTY OPEN-LABEL EXTENSION STUDY
    Reuter, Uwe
    Goadsby, Peter J.
    Lanteri-Minet, Michel
    Stites, Tracy
    Wen, Shihua
    Tenenbaum, Nadia
    Ferrari, Michel D.
    Pandhi, Shaloo
    CEPHALALGIA, 2020, 40 : 58 - 59
  • [27] Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine Patients with Prior Prophylactic Treatment Failure: Results from a Post-Hoc Analysis of the STRIVE study
    Pascual, J.
    Buse, D.
    Starling, A. J.
    Ailani, J.
    Zhang, F.
    Wen, S.
    Bilitou, A.
    Desai, P.
    Picard, H.
    Klatt, J.
    Mikol, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 409 - 409
  • [28] Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine Patients with Prior Prophylactic Treatment Failure: Results from a Post-Hoc Analysis of the STRIVE Study
    Pascual, J.
    Buse, D. C.
    Starling, A. J.
    Ailani, J.
    Zhang, F.
    Wen, S.
    Bilitou, A.
    Desai, P.
    Pichard, H.
    Klatt, J.
    Mikol, D.
    HEADACHE, 2018, 58 : 179 - 180
  • [29] Patient-Reported Outcomes from the STRIVE Trial: A Phase 3, Randomized, Double-Blind Study of Erenumab in Subjects with Episodic Migraine
    Buse, D. C.
    Lipton, R. B.
    Hallstrom, Y.
    Reuter, U.
    Tepper, S. J.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D. D.
    Lenz, R. A.
    HEADACHE, 2017, 57 : 198 - 199
  • [30] Sustained Efficacy and Safety of Erenumab in Patients With Episodic Migraine Who Failed 2-4 Prior Preventive Treatments: 2-Year Interim Results of the LIBERTY Open-label Extension Study
    Reuter, U.
    Goadsby, P. J.
    Lanteri-Minet, M.
    Stites, T.
    Wen, S.
    Tenenbaum, N.
    Ferrari, M.
    Pandhi, S.
    HEADACHE, 2020, 60 : 96 - 97
12345